Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Original 2012 Tian iMODEL

A six-factor additive score that stratifies the likelihood of complete secondary cytoreduction in recurrent epithelial ovarian cancer.

Evidence-based context for fast calculator use

Purpose:
Support multidisciplinary assessment before contemplated secondary cytoreductive surgery.
Population:
First platinum-sensitive recurrent epithelial ovarian cancer assessed before secondary cytoreduction.
Factors:
Initial FIGO stage, Primary-surgery residual disease, Progression-free interval, ECOG performance status, CA-125 at recurrence, Ascites
Reference:
Tian et al. Ann Surg Oncol. 2012;19:597-604. DOI 10.1245/s10434-011-1873-2.
HomeTian iMODEL for Ovarian Cancer Recurrence
Pin your most used calculators here by clicking the star in the dropdown.

Tian iMODEL for Ovarian Cancer Recurrence

months
U/mL

Clinical Context & Background

The original Tian international model stratifies patients with first platinum-sensitive recurrent epithelial ovarian cancer before contemplated secondary cytoreductive surgery. It uses initial FIGO stage, residual disease after primary surgery, progression-free interval, ECOG performance status, CA-125 at recurrence, and ascites. The model does not determine treatment eligibility or provide an individualized survival estimate.
Formula Logic
iMODEL = FIGO (0 or 0.8) + residual disease (0 or 1.5) + PFI (0 or 2.4) + ECOG (0 or 2.4) + CA-125 (0 or 1.8) + ascites (0 or 3.0). Scores ≤4.7 are low-risk; scores >4.7 are high-risk.

Reference Data

Tian scoreSource groupComplete cytoreduction in development cohort
0.0-4.7Low-risk group53.4%
>4.7-11.9High-risk group20.1%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Confirmed first platinum-sensitive recurrence of epithelial ovarian cancer.
  • Baseline assessment before contemplated secondary cytoreductive surgery.

How To Interpret

  • A score of 4.7 or less is the original Tian low-risk group; a score above 4.7 is the high-risk group.
  • The reported 53.4% and 20.1% complete-cytoreduction rates are development-cohort observations, not individualized probabilities.

What To Do Next

  • Use the result alongside imaging, surgical expertise, comorbidity, patient preferences, and multidisciplinary review.

Limitations

  • Not validated for primary disease, borderline or non-epithelial tumors, platinum-resistant disease, later recurrence after additional treatment, or post-treatment reassessment.
  • Does not replace AGO/DESKTOP assessment, specialist resectability review, or clinical judgment.
  • Does not incorporate the SOC-1 PET/CT investigator override.

Validated Population

International recurrent epithelial ovarian cancer cohorts undergoing evaluation for secondary cytoreduction.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed cases passed through visible production controls at iMODEL scores 0, exact cutoff 4.7, and maximum 11.9.
    • The <=4.7 low-risk and >4.7 high-risk branches rendered as expected.
    • No unexpected N/A, literal undefined value, stale control, unsupported gauge, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/imodel-ovarian-recurrence-2026-08-03.json.

  2. : Production browser validation

    • Ten source-backed cases were entered and submitted through the visible production controls at oncotoolkit.com across 11 browser submissions; all ten calculation and UI cases matched their expected results.
    • The matrix covered every source component, the raw 16-month PFI and 105 U/mL CA-125 transitions, the inclusive 4.7 group boundary, the below-6-month not-applicable path, and reset/repeat behavior without stale state.
    • Overall browser status was failed-console because production route loads emitted minified React hydration error #418; no calculator-specific console error or calculation mismatch was observed.

    Case-level production evidence is retained in validation/browser-production/imodel-ovarian-recurrence.json.

  3. : Input workflow simplified and revalidated

    • Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
    • Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
    • Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.

  4. : Full validation test

    • 384/384 source-oracle, engine, UI, boundary, malformed-input, applicability, trace, registry, report, history, and isolation checks passed with zero score difference.
    • This verifies implementation of the original 2012 model; it is not independent clinical validation, an individualized probability, or a treatment recommendation.

  5. : Source and input-contract correction

    • Restored all six original Tian weights, the 16-month PFI and 105 U/mL CA-125 cutoffs, the inclusive 4.7 low-risk boundary, and the source cohort outcome rates.
    • Removed favorable defaults, permissive summing, the unrelated ADNEX description, unsupported intermediate group, candidacy labels, and unverified outcome claims.
    • Added explicit diagnosis, recurrence-setting, assessment-timing, malformed-input, and platinum-sensitive population gates.

    Included in the current validation report.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

FIGO-Modified WHO Gestational Trophoblastic Neoplasia Risk Score 2026RMI (Risk of Malignancy Index)ROMA Score (Ovarian)

Frequently Asked Questions

When should Tian iMODEL for Ovarian Cancer Recurrence be used?

Use it for patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment when all required inputs and the intended clinical setting are confirmed.

Can Tian iMODEL for Ovarian Cancer Recurrence determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.